Date: 03 Jul 2013
The biology of thrombopoietin and thrombopoietin receptor agonists
- David J. Kuter
- … show all 1 hide
Thrombopoietin (TPO) is the major physiological regulator of platelet production. TPO binds the TPO receptor, activates JAK and STAT pathways, thus stimulating megakaryocyte growth and platelet production. There is no “sensor” of the platelet count; rather TPO is produced in the liver at a constant rate and cleared by TPO receptors on platelets. TPO levels are inversely proportional to the rate of platelet production. Early recombinant TPO molecules were potent stimulators of platelet production and increased platelets in patients with immune thrombocytopenia, chemotherapy-induced thrombocytopenia, myelodysplastic syndromes and platelet apheresis donors. Neutralizing antibodies formed against one recombinant protein and ended their development. A second generation of TPO receptor agonists, romiplostim and eltrombopag, has been developed. Romiplostim is an IgG heavy chain into which four TPO agonist peptides have been inserted. Eltrombopag is an oral small molecule. These activate the TPO receptor by different mechanisms to increase megakaryocyte growth and platelet production. After administration of either to healthy volunteers, there is a delay of 5 days before the platelet count rises and subsequently reaches a peak after 12–14 days. Both have been highly effective in treating ITP and hepatitis C thrombocytopenia. Studies in a wide variety of other thrombocytopenic conditions are underway.
Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem (Tokyo). 1995;118:229–36.
Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci (USA). 1994;91:11104–8.CrossRef
Hoffman RC, Andersen H, Walker K, et al. Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from ser1 to Arg246. Biochemistry (Mosc). 1996;35:14849–61.CrossRef
Kato T, Oda A, Inagaki Y, et al. Thrombin cleaves recombinant human thrombopoietin: one of the proteolytic events that generates truncated forms of thrombopoietin. Proc Natl Acad Sci (USA). 1997;94:4669–74.CrossRef
Gurney AL, Kuang WJ, Xie MH, Malloy BE, Eaton DL, de Sauvage FJ. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood. 1995;85:981–8.PubMed
Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood. 1995;86:4486–92.PubMed
Foster D, Hunt P. The biological significance of truncated and full-length forms of Mpl ligand. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, editors. Thrombopoiesis and thrombopoietins: molecular, cellular, preclinical, and clinical biology. Totowa: Humana Press; 1997. p. 203–14.CrossRef
Spivack JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood. 1989;73:90–9.
Borge OJ, Ramsfjell V, Veiby OP, Murphy MJ Jr, Lok S, Jacobsen SE. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro. Blood. 1996;88:2859–70.PubMed
Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997;90:2234–43.PubMed
Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood. 1997;89:1896–904.PubMed
Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res. 1995;55:3509–12.PubMed
Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood. 1996;88:803–8.PubMed
Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996;87:567–73.PubMed
Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood. 2000;95:795–801.PubMed
Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996;88:511–21.PubMed
Arnold JT, Daw NC, Stenberg PE, Jayawardene D, Srivastava DK, Jackson CW. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization. Blood. 1997;89:823–33.PubMed
Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93:2798–806.PubMed
Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530–5.PubMed
Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS). Blood. 2000;96:296a.
Goodnough LT, DiPersio J, McCullough J, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases platelet (PLT) count (CT) and apheresis yields of normal PLT donors:initial results. Transfusion (Paris). 1997;37:266S.
Kuter DJ. Whatever happened to thrombopoietin? Transfusion (Paris). 2002;42:279–83.CrossRef
Nplate prescribing information: Amgen, Inc; 2012.
Duffy KJ, Erickson-Miller C. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf D, Dillon SB, editors. Target validation in drug discovery. Burlington: Academic Press; 2007. p. 241–54.CrossRef
Erickson-Miller C, Delorme E, Giampa L, et al. Biological activity and selectivity for Tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. Blood. 2004;104:796a.
Erickson-Miller C, Delorme E, Iskander M, et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood. 2004;104:795a.CrossRef
Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood. 1996;87:1833–44.PubMed
Promacta prescribing information: GlaxoSmithKline, Inc; 2008.
Zimrin A, Chumsri S. Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim. Ann Hematol. 2013 [Epub ahead of print].
Parameswaran R, Soff G. Romiplostim in a case series of chemotherapy-induced thrombocytopenia. Blood. 2011;118:1170.
Winer E, Safran H, Karaszewska B, et al. Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): a phase I study. J Clin Onc. 2012;30:9117.
Rodeghiero F, George J, Rummel M, et al. Results from a phase IV open-label study evaluating changes in bone marrow morphology in adult immune thrombocytopenia (ITP) patients receiving romiplostim: analysis of the 1-year romiplostim cohort. Haematologia (Budap). 2012;97:611.
Brynes R, Orazi A, Verma S, Brainsky A, Bailey C, Bakshi K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with eltrombopag—data from the EXTEND Study. Blood. 2011;118:528.
Brynes R, Orazi A, Wong R, Bakshi K, Bailey C, Brainsky A. A longitudinal prospective study evaluating the effects of eltrombopag treatment on bone marrow in patients with chronic immune thrombocytopenia: interim analysis at 1 year. Blood. 2012;120.
Giagounidis A, Mufti G, Kantarjian H, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo(pbo)-controlled study. Blood. 2011;118:117.
Bennett I, Forssen U, Enger V, Nelson J. Risk of thrombotic events among patients with chronic idiopathic thrombocytopenia purpura (ITP). Haematologia (Budap). 2008;93(s1):125.
- The biology of thrombopoietin and thrombopoietin receptor agonists
International Journal of Hematology
Volume 98, Issue 1 , pp 10-23
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Industry Sectors
- David J. Kuter (1) (2)
- Author Affiliations
- 1. Harvard Medical School, Boston, MA, USA
- 2. Hematology Division, Yawkey 7858, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA